12
Participants
Start Date
August 31, 2013
Primary Completion Date
March 31, 2014
Study Completion Date
October 31, 2014
Interferon Gamma-1b
"Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection."
Children's Hospital of Philadelphia, Philadelphia
Friedreich's Ataxia Research Alliance
OTHER
Vidara Therapeutics Research Ltd
INDUSTRY
Children's Hospital of Philadelphia
OTHER